-
1.发明申请公开(公告)号：US20100261752A1
公开(公告)日：2010-10-14
申请号：US12758631
申请日：2010-04-12
IPC分类号： A61K31/439 , A61K31/4545 , A61P25/28
CPC分类号： A61K31/46 , A61K31/445 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K45/06 , A61K2300/00
摘要： The invention provides methods for the treatment of cognitive disorders utilizing specific 5-HT4 receptor agonist compounds, in particular, methods utilizing these compounds in combination with other agents, specifically acetylcholinesterase inhibitors, for the treatment of Alzheimer's disease and other cognitive disorders.
摘要翻译： 本发明提供了使用特定的5-HT 4受体激动剂化合物治疗认知障碍的方法，特别是利用这些化合物与其它试剂，特别是乙酰胆碱酯酶抑制剂联合用于治疗阿尔茨海默氏病和其他认知障碍的方法。
-
公开(公告)号：US09206159B2
公开(公告)日：2015-12-08
申请号：US13869199
申请日：2013-04-24
IPC分类号： C07D401/14 , A61K31/496 , A61K31/506 , A61K31/55 , C07D487/08 , C07D405/14 , A61K45/06
CPC分类号： C07D401/14 , A61K31/496 , A61K31/506 , A61K31/55 , A61K45/06 , C07D405/14 , C07D487/08
摘要： The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明提供式（I）化合物：其中变量在说明书中定义，或其药学上可接受的盐，其是丙型肝炎病毒的复制抑制剂。 本发明还提供包含这些化合物的药物组合物，使用这些化合物治疗丙型肝炎病毒感染的方法，以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号：US20150183761A1
公开(公告)日：2015-07-02
申请号：US14488520
申请日：2014-09-17
IPC分类号： C07D401/14 , C07D409/14 , C07D405/14
CPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , G01N33/5058
摘要： The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
摘要翻译： 本发明涉及式（I）的苯并咪唑 - 甲酰胺5-HT 4受体激动剂化合物，其中R 1和X如说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。 本发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗与5-HT 4受体活性有关的疾病的方法，以及可用于制备这些化合物的方法和中间体。
-
公开(公告)号：US20150065543A1
公开(公告)日：2015-03-05
申请号：US14521689
申请日：2014-10-23
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： C07D513/14 , C07D233/64 , C07D213/64 , C07D233/70 , C07D231/14 , C07D249/08 , C07D233/68 , C07D403/10
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及具有下式的化合物：其中：Ar，r，Y，Z，Q，W，X和R5-7如说明书中所定义，及其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20140194426A1
公开(公告)日：2014-07-10
申请号：US14062004
申请日：2013-10-24
IPC分类号： C07D413/14 , C07D263/34 , C07D413/12 , C07D413/10
CPC分类号： C07D263/34 , A61K31/421 , A61K31/422 , A61K31/4245 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/5377 , C07D263/38 , C07D413/10 , C07D413/12 , C07D413/14
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，Z，R 3，R 4和R 5如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US08735625B2
公开(公告)日：2014-05-27
申请号：US13755404
申请日：2013-01-31
申请人： Seok-ki Choi , Paul R. Fatheree , Ryan Hudson , Keith Jendza , Robert Murray McKinnell , Vivek Sasikumar
发明人： Seok-ki Choi , Paul R. Fatheree , Ryan Hudson , Keith Jendza , Robert Murray McKinnell , Vivek Sasikumar
IPC分类号： C07C239/00 , C07D257/00
CPC分类号： C07C237/20 , C07C243/32 , C07C319/12 , C07C323/22 , C07C323/41 , C07C323/60 , C07C2601/14 , C07D257/04
摘要： The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及式I化合物：其中Ar，r，R 3，X和R 5-7如说明书中所定义，及其药学上可接受的盐。 式I的化合物具有AT1受体拮抗剂活性和去皮质激素抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20140046075A1
公开(公告)日：2014-02-13
申请号：US13755404
申请日：2013-01-31
申请人： Seok-ki Choi , Paul R. Fatheree , Ryan Hudson , Keith Jendza , Robert Murray McKinnell , Vivek Sasikumar
发明人： Seok-ki Choi , Paul R. Fatheree , Ryan Hudson , Keith Jendza , Robert Murray McKinnell , Vivek Sasikumar
IPC分类号： C07D257/04 , C07C319/12
CPC分类号： C07C237/20 , C07C243/32 , C07C319/12 , C07C323/22 , C07C323/41 , C07C323/60 , C07C2601/14 , C07D257/04
摘要： The invention is directed to compounds of formula I: wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
摘要翻译： 本发明涉及式I化合物：其中Ar，r，R 3，X和R 5-7如说明书中所定义，及其药学上可接受的盐。 式I的化合物具有AT1受体拮抗剂活性和去皮质激素抑制活性。 本发明还涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号：US20130245087A1
公开(公告)日：2013-09-19
申请号：US13685148
申请日：2012-11-26
申请人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
发明人： Paul Allegretti , Seok-Ki Choi , Roland Gendron , Paul R. Fatheree , Keith Jendza , Robert Murray McKinnell , Darren McMurtrie , Brooke Olson
IPC分类号： C07D233/64
CPC分类号： C07D233/70 , A61K31/415 , A61K31/4164 , A61K31/417 , A61K31/4188 , A61K31/4196 , A61K31/4412 , A61K45/00 , A61K45/06 , C07D207/36 , C07D207/46 , C07D213/64 , C07D213/89 , C07D231/14 , C07D233/64 , C07D233/68 , C07D233/90 , C07D249/08 , C07D255/02 , C07D401/12 , C07D403/10 , C07D513/04 , C07D513/14
摘要： The invention is directed to compounds having the formula: wherein: Ar, r, R2-3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
-
公开(公告)号：US08481549B2
公开(公告)日：2013-07-09
申请号：US13008262
申请日：2011-01-18
IPC分类号： A61K31/497 , A61K31/4436
CPC分类号： C07D409/10 , C07D207/34 , C07D277/56 , C07D307/68 , C07D333/38 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/10 , C07D405/10 , C07D413/10 , C07D417/06 , C07D417/10 , C07D417/14
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
-
公开(公告)号：US08350027B2
公开(公告)日：2013-01-08
申请号：US13346237
申请日：2012-01-09
申请人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
发明人： Brooke Blair , Paul R. Fatheree , Melissa Fleury , Roland Gendron , Ryan Hudson , Robert Murray McKinnell , Michael Wilson
IPC分类号： C07D413/14 , C07D401/14 , C07D259/00 , C07D271/06 , C07D231/10
CPC分类号： C07D403/10 , C07D231/12 , C07D231/14 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/10
摘要： In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
摘要翻译： 一方面，本发明涉及具有下式的化合物：其中：Ar，Z，R 3，R 4和R 5如说明书中所定义，或其药学上可接受的盐。 这些化合物具有AT1受体拮抗剂活性和neprilysin抑制活性。 另一方面，本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
-
-
-
-
-
-
-
-
搜索结果
93 条记录 (耗时 0.082 秒)
